<DOC>
	<DOCNO>NCT02637557</DOCNO>
	<brief_summary>The objective study evaluate safety , efficacy , dose-response relationship IW-3718 administer orally patient GERD continue experience GERD symptom receive once-daily ( QD ) , standard-dose PPIs</brief_summary>
	<brief_title>A Randomized , Double-blind , Placebo-controlled , Trial IW-3718 8 Weeks Patient With Symptomatic GERD</brief_title>
	<detailed_description>This study multicenter , randomize , double-blind , placebo-controlled , parallel-group , 8-week study , consist 3 distinct period : screening period , pretreatment period , treatment period . The study enroll patient GERD continue experience GERD symptom receive QD , standard-dose PPI therapy . Eligible patient continue take PPI randomize placebo one three dos study drug .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Patient ambulatory , communitydwelling male nonpregnant female least 18 year old Screening Visit . Lactating female must agree breastfeed . Patient diagnosis GERD report experience GERD symptom ( heartburn regurgitation ) â‰¥ 4 day per week 8 week Screening Visit take standard QD PPI therapy . Patient may meet excluded condition specify protocol Patient alarm symptom include limited GI bleeding , anemia , vomit , dysphagia , unexpected weight loss time Screening Pretreatment Periods Patient history clinically significant hypersensitivity allergy excipients contain study medication ( active placebo ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>